$AVTR

Avantor (AVTR) received a Buy rating from Zacks, with upward revisions to its full-year earnings estimates. Analysts are optimistic about its earnings outlook, despite flat sales and declining net income in Q2 2026. The company projects $7.1 billion revenue and $651.0 million earnings by 2029, requiring 2.8% yearly revenue growth and a $1,229.0 million earnings increase from -$578.0 million today.

Avantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.

Avantor Inc. (NYSE: AVTR) raised its full-year 2026 outlook after Q2 results beat expectations. Q2 net sales were $1.69B, up 0.5% YoY, with organic revenue down 0.4% (ex FX). Adjusted EPS was $0.21. Net income fell to $38.1M. Operating cash flow was $178.2M, free cash flow $142.8M, and $112.1M debt was repaid.

Avantor’s Q2 results beat Wall Street on revenue and non-GAAP earnings, with management citing progress in its Revival transformation, especially in the VWR distribution and services segment. CEO Emmanuel Ligner and CFO Steve Eck discussed drivers like e-commerce upgrades, contract wins, digital metrics, margin stability, and free cash flow. Revenue was $1.69B vs $1.61B est, adjusted EPS $0.21 vs $0.19, and full-year adjusted EPS guidance $0.82.

Avantor (AVTR) reported Q2 2026 sales of $1,692.3M, slightly up, but GAAP net income fell to $38.1M and EPS to $0.06. The company raised full-year 2026 guidance based on better-than-expected adjusted results and earlier organic growth in VWR Distribution & Services. The article also cites 2029 projections of $6.9B revenue and $566.4M earnings.

Strategic Execution and Performance Drivers Management attributes the second quarter outperformance to the 'Revival' program, which focuses on commercial excellence, operational performance, and organizational simplification. The VWR Distribution & Services segment returned to organic growth earlier than anticipated, driven by deliberate actions to strengthen large global customer relationships and improve e-commerce engagement.

Simply Wall St reports Avantor (AVTR) shares fell about 3.7% to around $13.86 after Q2 results. The company posted Q2 revenue of $1.69b and adjusted EPS of $0.21, with free cash flow of $152m and leverage near 3.3x. Revenue was roughly flat YoY, but net income fell about 41% YoY and trailing net income turned to a loss.

Biotech gainers included SciSparc (SPRC) after its subsidiary NeuroThera Labs completed internal validation of a quantum sampling platform. Avantor (AVTR) rose after Q2 results and raised 2026 adjusted EPS to $0.80-$0.83. NeoGenomics (NEO) lifted 2026 revenue guidance to $802-$806M. Other movers: Alvotech (ALVO) on FDA facility inspection, Sanara MedTech (SMTI) to be acquired by MiMedx (MDXG), and LB Pharmaceuticals (LBRX) after a ~$150M private placement.

US equity futures edged higher as S&P 500 and Nasdaq 100 contracts were up about 0.2% premarket, despite a sharp Kospi selloff in Asia and a 5% oil jump. The article cites earnings and guidance moves for several companies, including MSFT and META, plus notable premarket moves: AVTR +4%, BE +8%, CAT -4%, and others. It also notes a Fed decision later today with markets pricing a 32% hike chance.

Avantor (NYSE:AVTR) reported Q2 CY2026 revenue of $1.69 billion, flat year over year but 4.9% above Wall Street estimates, according to the article. Non-GAAP adjusted EPS was $0.21, up 11% versus analysts’ consensus, though down from $0.24 a year earlier. The stock rose about 7% to $13.28 after the release.